Predicting progesterone sensitivity in early endometrial cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a prediction model for progesterone sensitivity in patients diagnosed with early endometrial carcinoma or atypical endometrial hyperplasia. After diagnosis via hysteroscopy, eligible patients will receive daily doses of Medroxyprogesterone acetate or Megestrol acetate, with regular evaluations through hysteroscopy every three months. The study will analyze patient-derived tumor-like cell clusters to assess lipid content and construct a predictive model based on the collected data from 148 cases. The model will then be validated to determine its effectiveness in predicting treatment responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a confirmed pathological diagnosis based upon hysteroscopy: atypical endometrial hyperplasia or histologically prove well-differentiated EEC G1 without myometrial invasion
* No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound
* Have a desire for remaining reproductive function or uterus
* Good compliance with adjunctive treatment and follow-up

Exclusion Criteria:

* Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
* Pregnancy or potential pregnancy
* Confirmed diagnosis of any cancer in reproductive system
* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
* Hypersensitivity or contradiction for using MPA or MA
* With other factors of reproductive dysfunction;
* Strong request for uterine removal or other conservative treatment

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: WANG JIANLIU, PhD/MD
• Email: wangjianliu1203@163.com
• Phone: 8601088324383

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy screening for early endometrial cancer in regional China

  A non-invasive blood test using cell-free DNA is being tested to see if it can detect early endometrial cancer and tell apart benign from malignant uterine lesions.

  Recruiting Guizhou Provincial People's Hospital · Guiyang, Guizhou · NCT07892755

• Intrauterine type III collagen injection plus progestin for fertility-preserving endometrial cancer or atypical hyperplasia

  This test sees if adding an intrauterine injection of recombinant humanized type III collagen to high‑dose progestin helps women with early endometrial cancer or atypical hyperplasia preserve fertility and achieve tumor remission.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07377734

• Using GnRHa and Letrozole for Obese Women with Progestin-Insensitive Endometrial Cancer

  This study is testing a new treatment combining GnRH antagonist and letrozole to see if it helps obese women with a specific type of endometrial cancer that hasn't responded to standard therapy.

  Recruiting at 2 sites Phase 2/3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT06379113

• Combining GnRHa and Letrozole for Non-obese Patients with Endometrial Cancer

  This study is testing if a combination of GnRHa and letrozole can help non-obese patients with early-stage endometrial cancer keep their fertility when standard treatments haven't worked.

  Recruiting at 2 sites Phase 2/3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT05316935

• Weight management combined with hormonal treatment for women with endometrial atypical hyperplasia

  This study is testing if combining weight management with hormonal treatments can help obese women with endometrial atypical hyperplasia who want to keep their fertility have better treatment results and pregnancy chances.

  Recruiting Phase 2/3 Fudan University · Shanghai · NCT05316493

• Detecting gynecologic cancers using DNA markers in vaginal fluid and blood

  This study is testing a new way to detect endometrial, ovarian, and cervical cancers early by looking for specific DNA markers in the vaginal fluid and blood of women with abnormal bleeding.

  Recruiting at 21 sites Mayo Clinic · Phoenix, Arizona and 24 other locations · NCT05051722

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.